Clinical Trial Update: MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MGTA-456 in patients with inherited metabolic disorders undergoing HSCT; study completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Metabolic Disorders

Drugs mentioned

• MGTA-456

Snippet

Sponsor: Magenta Therapeutics, Inc. | Conditions: Inherited Metabolic Disorders (IMD) | Phase 2 | Status: COMPLETED | Results posted: 2021-10-28